A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)
Latest Information Update: 15 Oct 2020
At a glance
- Drugs Anumigilimab (Primary)
- Indications COVID 2019 infections; Interstitial lung diseases
- Focus Therapeutic Use
- Sponsors CSL Behring
- 12 Oct 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to business reasons, not safety issues.
- 09 Sep 2020 Planned initiation date changed from 1 Aug 2020 to 1 Sep 2020.
- 21 Aug 2020 New trial record